Images List Premium Download Classic

Steatohepatitis

Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Heterocyclic compounds useful in the treatment of disease
October 18, 2018 - N°20180297962

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (nash); ocular diseases such as diseases involving retinal ...
Aryl acylsulfonamides as blt1 antagonists
October 11, 2018 - N°20180291017

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid ...
Ask1 inhibitor compounds and uses thereof
October 11, 2018 - N°20180291002

Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.. .
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods for diagnosing and evaluating non-alcoholic steatohepatitis
Genfit
September 20, 2018 - N°20180265924

The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (nash), for determining the activity, the stage, or the severity of nash or for classifying a subject as a potential receiver or non receiver of a treatment of nash using circulating mirnas and other blood circulating markers of liver damage, e.g. Alpha 2 macroglobulin, hba1c, n-terminal pro-peptide ...
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
September 13, 2018 - N°20180259537

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.
Cb2 receptor internalization
Arena Pharmaceuticals, Inc.
September 06, 2018 - N°20180252736

Certain compounds and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor, including its internalization in a cell, are provided. Certain methods of identifying compounds that increase cb2 receptor internalization are also provided.
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
Sanofi
August 23, 2018 - N°20180236037

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an fgf21 (fibroblast growth factor 21) compound and a glp-1r (glucagon-like peptide-1 receptor) agonist with optimized glp-1r agonist/fgf21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, ...
Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
Eiger Group International, Inc.
July 19, 2018 - N°20180200228

Disclosed herein are methods for use of r-chloroquine or clemizole or combinations of r-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory′ conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject.
Systems, devices and methods for performing medical procedures in the intestine
Fractyl Laboratories, Inc.
July 12, 2018 - N°20180193590

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
The University Of British Columbia
July 12, 2018 - N°20180193413

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive ...
Fatty acid amides for the prevention and/or treatment of steatohepatitis
FundaciÓ Institut Mar D'investigacions MÈdiques
July 12, 2018 - N°20180193293

The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis ...
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
July 05, 2018 - N°20180185330

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Non-alcoholic fatty liver disease biomarkers
The Regents Of The University Of California
June 07, 2018 - N°20180155787

Methods, compositions, kits, and systems for characterizing the non-alcoholic fatty liver disease (nafld) state of a subject are provided. In some embodiments the methods, compositions, kits, and systems comprise at least one mirna selected from the differentially expressed mirnas listed in at least one of tables 1-4, 10-14, and 28-29.
Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty ...
Metabolic Technologies, Inc.
June 07, 2018 - N°20180153827

Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (nafld), alcoholic liver disease (ald) or nonalcoholic steatohepatitis (nash), are described. The compounds of the present invention are gamma-ketoaldehyde scavengers..
Method for screening pharmaceuticals for treatment of steatohepatitis using n-terminal dimerization of apoptosis signal-regulated kinase1
Wuhan University
May 31, 2018 - N°20180149638

A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing n-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.. .
Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention ...
Pierre Fabre Medicament
May 24, 2018 - N°20180140609

The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.. .
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
May 10, 2018 - N°20180125870

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Treatment for hepatic fibrosis
Galmed Research And Development Ltd.
May 10, 2018 - N°20180125862

The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), employing the use of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (...
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
Askat Inc.
May 10, 2018 - N°20180125832

This invention is directed to prostaglandin e2 receptor 4 (ep4) antagonists useful in the treatment of nonalcoholic steatohepatitis (nash)-associated liver cancer in a human or animal. The method comprises administering one or more of compound a, compound b or compound c, or pharmaceutically acceptable salts thereof, as the ep4 antagonist(s).
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical ...
Deuterx, Llc
May 03, 2018 - N°20180117026

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.. .
Loading